Satellos Bioscience (TSE:MSCL) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Satellos Bioscience has achieved a significant milestone by dosing the first patient with Duchenne muscular dystrophy (DMD) in their Phase 1b clinical trial of SAT-3247. This development follows the successful completion of earlier safety trials, indicating the drug’s potential as a safe and tolerable treatment option for DMD. The trial aims to enroll up to 10 participants to further assess the drug’s safety and pharmacokinetics.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
